Philippe Moreau, MD, of Nantes University Hospital, Nantes, France, explores new strategies for newly diagnosed multiple myeloma (MM) patients. Specifically discussed are results from the Phase III MAIA study (NCT02252172) as well as the use of daratumumab in transplant-eligible patients per the CASSIOPEIA trial (NCT02541383). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).